CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug mimics natural protein to calm overactive immune system in nerve disease
Disease control OngoingThis Phase 2 trial is testing a new drug called NVG-2089 in 60 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves. The drug is designed to mimic a natural protein (IVIg) to reduce inflammation and improve nerve…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Nuvig Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a stem cell transplant stop the immune system from attacking the brain?
Disease control OngoingThis phase 2 trial tests whether high-dose chemotherapy followed by a stem cell transplant can stop the immune system from attacking the nervous system in people with autoimmune neurologic diseases like multiple sclerosis and stiff person syndrome. The treatment aims to weaken th…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for nerve disease: batoclimab safety trial expands
Disease control ENROLLING_BY_INVITATIONThis study checks the long-term safety of a drug called batoclimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 108 people who finished an earlier batoclimab study will get weekly injections fo…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
One Patient's last hope: stem cells for rare nerve disease
Disease control NO_LONGER_AVAILABLEThis study gives one patient with CIDP access to their own stored stem cells to see if it's safe and might help. The patient receives multiple infusions over 44 weeks and is followed for a year. Because it's only one person, the results are very limited.
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can a cancer drug help CIDP patients ditch their meds?
Disease control TerminatedThis study planned to test the drug rituximab in people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. The goal was to see if rituximab could help certain patients stop their current treatments and achieve long-…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 26, 2026 18:31 UTC
-
New test could predict falls in muscle disease patients
Diagnosis ENROLLING_BY_INVITATIONThis study aims to create a simple test battery to determine fall risk in people with neuromuscular disorders, such as muscular dystrophy or ALS. Researchers will assess 108 participants using several physical tests like walking, standing, and rising from a chair. The goal is to …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: LMU Klinikum • Aim: Diagnosis
Last updated Jun 26, 2026 16:30 UTC